GCP
TCRX icon

GSA Capital Partners’s TScan Therapeutics TCRX Stock Holding History

GSA Capital Partners’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$383K Buy
378,960
+152,796
+68% +$163K 0.02% 1093
2025
Q4 		$226K Buy
+226,164
New +$327K 0.02% 1339
2025
Q2 		– Sell
-41,817
Closed -$58K – 2138
2025
Q1 		$58K Buy
+41,817
New +$90.5K 0.01% 1540

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

GSA Capital Partners's TCRX Position: Q1 2026 in Review

GSA Capital Partners increased its TScan Therapeutics (TCRX) stake by 68% in Q1 2026, buying an estimated $163K and bringing the position to 378,960 shares worth $383K. The position accounts for 0.02% of the portfolio, ranked #1093.

GSA Capital Partners first reported a position in TCRX in Q1 2025 and has held it in 3 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

  • GSA Capital Partners held 378,960 shares of TScan Therapeutics worth $383K as of Q1 2026.
  • GSA Capital Partners bought 152,796 TScan Therapeutics shares in Q1 2026, an estimated $163K.
  • TScan Therapeutics made up 0.02% of GSA Capital Partners's portfolio in Q1 2026, its #1093 holding.
  • GSA Capital Partners first reported a position in TScan Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.